Don’t delay: Cancer patients need both doses of COVID vaccineMarch 15, 2021Multiple MyelomaAMLBreast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung Cancer
How has the pandemic affected rural and urban cancer patients?February 18, 2021Breast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell DisordersMelanoma
Checkpoint inhibitors’ ‘big picture’ safety shown with preexisting autoimmune diseasesFebruary 16, 2021MelanomaOncology
Managing cancer outpatients during the pandemic: Tips from MSKCCFebruary 8, 2021Breast CancerGenitourinary CancerHead & Neck/Thyroid CancersLung CancerMelanomaOncology
COVID-19 vaccination in cancer patients: NCCN outlines prioritiesFebruary 1, 2021Breast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell DisordersMelanoma
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggestNovember 25, 2020Genitourinary CancerLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMelanomaOncologyLung Cancer
Neoadjuvant immunotherapy combo produces high response rate in melanomaNovember 25, 2020MelanomaOncology
Low threshold to biopsy atypical lesions may ID vulvar melanoma early, experts sayNovember 16, 2020MelanomaOncology
Real-world results with checkpoint inhibitors found inferior to trial resultsOctober 30, 2020Lung CancerMelanomaHead & Neck/Thyroid CancersGenitourinary Cancer
Lower BP and better tumor control with drug combo?October 26, 2020Lung CancerBreast CancerGenitourinary CancerHead & Neck/Thyroid CancersLymphoma & Plasma Cell DisordersMelanoma
